TOH edition: Friday, 23 October 2026 · Health & Medicine
More time without cancer returning: personalised vaccine cut melanoma recurrence risk by 42% in a large trial
Reported by statnews.com
Publisher date:
A personalised mRNA cancer vaccine developed by Moderna and Merck reduced melanoma recurrence risk by 42% compared with standard treatment in a large clinical trial. Patients lived significantly longer without their cancer returning, a result oncologists described as an important advance.
The findings show personalised cancer vaccines can help melanoma patients stay free of recurrence longer, while opening a possible path to treatments for other cancers.
Read the original report at statnews.com (opens in a new tab) →
Read the full front page of Friday, 23 October 2026 →
Get tomorrow's front page
Five reasons to believe in progress, delivered once a day.